Skip to content
  • Thursday, 27 August 2026
  • 7:09 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Pharmaceutical R&D

Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia

Teuku Ryan Jun 27, 2026 0

Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…

Read More
Data Science & Bioinformatics

Leveraging Mimesis for Secure Data Science: A Comprehensive Guide to Anonymizing Production Data.

Evan Lee Salim May 20, 2026 0

In an increasingly data-driven world, the ability to harness the power of vast datasets is paramount for innovation, yet it…

Read More
Prenatal Chlorpyrifos Exposure Linked to Lasting Brain Alterations and Reduced Motor Function in ChildrenInnovative Spin Polarized Fuel Mix Offers Path to More Efficient and Affordable Fusion Energy SystemsUnveiling Earth’s Hidden Highways: First Global Maps Reveal Vast Underground Fungal Networks Crucial for Life and ClimateOregon State University Researchers Unveil Real-Time Chemical Insights Into Alzheimer’s Protein Clumping and Potential Reversal Strategies
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactMEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ